# Pathobiology and clinical significance of malignant pleural effusions

## TL;DR

This paper reviews the biology and clinical challenges of malignant pleural effusion in advanced cancer, aiming to improve patient outcomes through better understanding and research.

## Contribution

The paper systematically reviews current knowledge and identifies key gaps in MPE biology and tumor-immune interactions.

## Key findings

- MPE is associated with high morbidity and mortality, with a median survival of 3–12 months.
- The paper highlights unresolved questions about tumor-immune interactions in the pleural microenvironment.
- Promising research directions are proposed to translate biological insights into clinical improvements.

## Abstract

Metastatic malignant pleural effusion (MPE) represents advanced-stage cancer and is defined by the establishment of metastatic tumor foci within the pleural space. It is most commonly associated with high degrees of morbidity and mortality. Annually, over 150,000 cancer patients in the United States develop MPE, which is associated with a dismal median survival of 3–12 months. As such, efforts must be made to understand the complex biological factors driving MPE pathophysiology. In this review, we discuss what is currently known and identify knowledge gaps regarding the intrinsic MPE biology of cancer cells and the heterotypic interactions between tumor cells and the immunologic pleural ecosystem. Furthermore, we discuss the clinical opportunities of studying MPE and identify promising directions for MPE research that may lead to a deeper understanding of the disease, ultimately aiming to enhance clinical outcomes for patients with advanced cancer.

In this review, CV Pecot, BG Vincent, J Akulian and colleagues discuss the cellular and molecular mechanisms driving metastatic malignant pleural effusion, highlight unresolved questions regarding tumor-immune interactions within the pleural microenvironment, and propose avenues to translate these insights into improved outcomes for patients with advanced cancer.